Amyloid Cardiomyopathy

The Role of Cardiovascular Magnetic Resonance Imaging in Heart Failure

Heart failure (HF) can be defined haemodynamically as any abnormality of cardiac structure or function resulting in a failure to deliver oxygen at a rate adequate for tissue requirements, despite normal filling pressures – or only at the expense of increased filling pressures.1 Around half of patients with HF have reduced left ventricle ejection fraction (LVEF; EF <40 %) at rest (HF-REF).2

Cardiac Amyloid – An Update

Amyloidosis is a condition characterised by accumulation of pathologic fibrillar proteins in organs causing dysfunction.1 Several protein precursors have been shown to cause amyloidosis.2 Cardiac amyloidosis, when waxy, starch-like deposits infiltrate the heart, is most commonly secondary to the accumulation of amyloid fibrils derived from immunoglobulin light chains (AL) or transthyretin (ATTR).

Diagnosis and Management of Cardiomyopathies - A Focus on Genetics, Cardiac Magnetic Resonance and Clinical Features

According to the latest position statement of the European Society of Cardiology (ESC), cardiomyopathies (CMP) are defined as “myocardial disorders in which the heart muscle is structurally and functionally abnormal, in the absence of coronary artery disease, hypertension, valvular disease and congenital heart disease sufficient to cause the observed myocardial abnormality”.1

Where's the Beef? A Case of Left Ventricular Hypertrophy that Isn't

A 35-year-old man is admitted for evaluation of non-ST-elevation myocardial infarction (STEMI) and heart failure. He has a history of leukemia treated with chemotherapy and radiation as a child, but has not had a cardiac evaluation in 10 years. He had been well until he developed dyspnea with exertion that progressed to dyspnea at rest over two days. At presentation, his blood pressure is 80/60mmHg, his heart rate is 110bpm, and his oxygen saturation is 91% in room air.